PADMANEE SHARMA to CTLA-4 Antigen
This is a "connection" page, showing publications PADMANEE SHARMA has written about CTLA-4 Antigen.
Connection Strength
6.471
-
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun. 2021 11 04; 12(1):6375.
Score: 0.581
-
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-na?ve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer. 2021 10; 9(10).
Score: 0.577
-
Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 2020 02; 20(2):75-76.
Score: 0.514
-
Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner. Cancer Immunol Res. 2019 Nov; 7(11):1803-1812.
Score: 0.499
-
Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest. 2018 08 31; 128(9):3813-3818.
Score: 0.463
-
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers. Clin Cancer Res. 2019 02 15; 25(4):1233-1238.
Score: 0.463
-
Loss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016 Oct 06; 167(2):397-404.e9.
Score: 0.407
-
Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined a-CTLA-4+a-PD-1 therapy. Nat Commun. 2016 08 08; 7:12335.
Score: 0.404
-
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res. 2013 Oct; 1(4):229-34.
Score: 0.328
-
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.
Score: 0.142
-
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
Score: 0.135
-
Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. Cell. 2019 Nov 14; 179(5):1177-1190.e13.
Score: 0.127
-
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response. Clin Cancer Res. 2019 06 01; 25(11):3469-3470.
Score: 0.123
-
Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States. Immunity. 2019 04 16; 50(4):1084-1098.e10.
Score: 0.121
-
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. J Clin Invest. 2018 04 02; 128(4):1338-1354.
Score: 0.112
-
Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunol Res. 2018 02; 6(2):189-200.
Score: 0.112
-
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell. 2017 Sep 07; 170(6):1120-1133.e17.
Score: 0.108
-
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
Score: 0.105
-
Immune Checkpoint Therapy and the Search for Predictive Biomarkers. Cancer J. 2016 Mar-Apr; 22(2):68-72.
Score: 0.098
-
The future of immune checkpoint therapy. Science. 2015 Apr 03; 348(6230):56-61.
Score: 0.092
-
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med. 2014 Apr 07; 211(4):715-25.
Score: 0.086
-
CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy. Cancer Immunol Res. 2014 Feb; 2(2):167-76.
Score: 0.084
-
Prostate cancer: combination of vaccine plus ipilimumab--safety and toxicity. Nat Rev Urol. 2012 May 08; 9(6):302-3.
Score: 0.075
-
Identification of human regulatory T cells in the setting of T-cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptide. Cancer Discov. 2012 Feb; 2(2):122-30.
Score: 0.073
-
The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res. 2011 Aug 15; 71(16):5445-54.
Score: 0.071
-
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010 May 15; 16(10):2861-71.
Score: 0.065
-
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A. 2009 Feb 24; 106(8):2729-34.
Score: 0.060
-
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A. 2008 Sep 30; 105(39):14987-92.
Score: 0.059
-
Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun. 2008 May 27; 8:9.
Score: 0.057
-
ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype. J Exp Med. 2024 Apr 01; 221(4).
Score: 0.043
-
The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role? Eur J Cancer. 2024 Feb; 198:113501.
Score: 0.042
-
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. J Immunother Cancer. 2021 05; 9(5).
Score: 0.035
-
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018 12; 24(12):1804-1808.
Score: 0.030
-
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383.
Score: 0.030
-
Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice. Adv Exp Med Biol. 2018; 995:97-116.
Score: 0.028
-
Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients. J Cutan Pathol. 2017 Dec; 44(12):1080-1086.
Score: 0.027
-
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun. 2017 02 13; 8:14340.
Score: 0.026
-
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
Score: 0.025
-
Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 2015; 7(9):967-980.
Score: 0.024
-
Cancer immunotherapy highlights from the 2014 ASCO Meeting. Cancer Immunol Res. 2014 Aug; 2(8):714-9.
Score: 0.022